+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Deep Brain Stimulation in Parkinson's Disease Market - Global Forecast 2026-2032- Product Image
Deep Brain Stimulation in Parkinson's Disease Market - Global Forecast 2026-2032- Product Image
New

Deep Brain Stimulation in Parkinson's Disease Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 198 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5532737
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Deep Brain Stimulation in Parkinson’s Disease Market continues to evolve, propelled by rapid device innovation and shifting healthcare delivery models. Senior executives require actionable intelligence on clinical adoption, risk management, and commercial positioning to navigate this complex neuromodulation landscape effectively.

Market Snapshot: Deep Brain Stimulation in Parkinson’s Disease Market

Demonstrating robust expansion, the Deep Brain Stimulation in Parkinson’s Disease Market climbed from USD 1.41 billion in 2025 to USD 1.61 billion in 2026 and is projected to achieve USD 4.02 billion by 2032, registering a CAGR of 16.15%. Technological advancements, a growing community of stakeholders, and heightened focus on policy and supply chain priorities all play critical roles. The market’s competitive environment features established medtech organizations alongside newer neuromodulation entrants, each advancing adaptive stimulation, modular system enhancements, and increased digital integration. Adaptation to regulatory change and supply chain complexity remains essential for sustained growth.

Scope & Segmentation

  • Technology Categories: Covers adaptive systems—including sensing-enabled, closed-loop platforms—that coexist with traditional fixed-parameter solutions, offering flexibility in clinical programming and patient care.
  • Component Portfolios: Encompasses implantable pulse generators, leads, extensions, and programming interfaces, providing comprehensive solutions for procedure optimization and ongoing device management.
  • Care Settings: Addresses hospitals, ambulatory surgical centers, and specialty neurology clinics, each presenting distinct demands for workflow integration and patient management protocols.
  • Channel Strategies: Includes direct sales and distribution partner networks, structured to enable customized clinical service delivery and ensure broad market coverage with high service consistency.
  • Regions: Focuses on the Americas’ established tertiary care infrastructure, Europe, Middle East & Africa’s variable regulatory regimes and payer landscapes, and Asia-Pacific’s fast-growing footprint characterized by infrastructure differences and expanding provider networks.

Key Takeaways for Senior Decision-Makers

  • Adaptive stimulation platforms equipped with sensing technology are transforming clinical practice by enabling individualized programming and real-time patient monitoring, which demand evolving clinical protocols and heightened training.
  • Interoperability among device components and seamless integration into digital care networks support device optimization and remote follow-up, furthering continuity of care and potentially strengthening patient outcomes.
  • Well-developed regulatory and payer environments now emphasize real-world data and direct demonstration of clinical effectiveness, increasing the need for transparent analytics and post-market evidence collection.
  • Resilient supply chains and adaptive procurement models are vital, given ongoing global disruptions that affect availability and the economics of device deployment in multiple regions.
  • Strategic alignment between product design and clinical workflow ensures efficient processes in hospitals and surgical centers, while advanced analytics capabilities support care delivery in neurology clinics.
  • Balanced commercial approaches—combining direct clinician engagement with scalable distributor partnerships—are necessary to expand reach without compromising the quality of training or device support.

Tariff Impact on Market Operations

Recent tariff increases in the United States have altered cost structures and operational strategies for neuromodulation stakeholders. Manufacturers are adjusting supplier relationships, qualifying alternative sources, and in some instances, implementing regional manufacturing to enhance resilience. These adaptations are essential for balancing total cost, product quality, and supply continuity. Companies with vertically integrated production or local manufacturing are better equipped to withstand supply shocks, while others may face increased procurement costs and production delays. Healthcare providers are increasingly vigilant about supplier stability and pricing, as supply chain shifts can influence care delivery schedules and patient access.

Methodology & Data Sources

This analysis leverages mixed-methods research, including in-depth interviews with clinicians, device programmers, procurement executives, and logistics experts. Data sources were triangulated using peer-reviewed clinical literature, regulatory documentation, patent reviews, and disclosures of component sourcing. External clinical advisor oversight and comprehensive data validation ensured reliability and accuracy throughout the research process.

Why This Report Matters

  • Delivers a practice-focused synthesis of clinical, commercial, and regulatory developments accelerating the adoption of advanced neuromodulation in Parkinson’s disease treatment.
  • Equips senior leadership with clear recommendations for technology procurement, supply chain optimization, and commercialization, helping manage evolving policy challenges.
  • Supports strategic decision-making by connecting commercial prospects with pathways for measurable and sustainable clinical outcomes.

Conclusion

Success in the Deep Brain Stimulation in Parkinson’s Disease Market depends on harnessing technological innovation, strengthening supply chains, and fostering clinician engagement. A coordinated approach to product, commercial, and operational management will position organizations to respond effectively to global and regional shifts.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Deep Brain Stimulation in Parkinson’s Disease Market, by Technology
8.1. Adaptive
8.1.1. Motion Feedback
8.1.2. Neural Feedback
8.2. Conventional
9. Deep Brain Stimulation in Parkinson’s Disease Market, by Component
9.1. Extension
9.2. Implantable Pulse Generator
9.3. Lead
9.4. Programmer
10. Deep Brain Stimulation in Parkinson’s Disease Market, by End User
10.1. Ambulatory Surgical Centers
10.2. Hospitals
10.3. Specialty Clinics
11. Deep Brain Stimulation in Parkinson’s Disease Market, by Distribution Channel
11.1. Direct Sales
11.2. Distribution Partner Networks
12. Deep Brain Stimulation in Parkinson’s Disease Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Deep Brain Stimulation in Parkinson’s Disease Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Deep Brain Stimulation in Parkinson’s Disease Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Deep Brain Stimulation in Parkinson’s Disease Market
16. China Deep Brain Stimulation in Parkinson’s Disease Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Abbott Laboratories
17.6. Aleva Neurotherapeutics SA
17.7. Beijing PINS Medical Co., Ltd.
17.8. Bioinduction Ltd.
17.9. Boston Scientific Corporation
17.10. Deep Brain Innovations LLC
17.11. FHC, Inc.
17.12. Functional Neuromodulation Ltd.
17.13. Inomed Medizintechnik GmbH
17.14. Integer Holdings Corporation
17.15. LivaNova, plc
17.16. Magstim Company Ltd.
17.17. Medtronic plc
17.18. Neurology Solutions
17.19. NeuroMetrix, Inc.
17.20. NeuroPace, Inc.
17.21. NeuroSigma, Inc.
17.22. Newronika S.r.l.
17.23. Nuvectra Corporation
17.24. Renishaw plc
17.25. SceneRay Corporation Ltd.
17.26. Soterix Medical Inc.
17.27. Suzhou PINS Medical Co., Ltd.
17.28. Synapse Biomedical, Inc.
17.29. Zynex, Inc.
List of Figures
FIGURE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY EXTENSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY EXTENSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY EXTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEAD, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEAD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEAD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PROGRAMMER, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PROGRAMMER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PROGRAMMER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 48. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 49. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 50. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 51. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 52. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 53. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 55. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 56. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 57. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 58. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 59. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 61. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 62. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 63. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 71. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 73. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 74. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 75. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 76. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 79. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 80. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 81. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 85. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 86. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 87. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 98. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 99. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 100. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 104. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 105. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 106. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 110. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 111. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 112. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 116. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 117. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 118. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 122. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 123. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 124. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 126. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 128. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 129. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 130. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 134. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 135. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 136. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 137. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 140. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 141. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
TABLE 142. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
TABLE 143. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Deep Brain Stimulation in Parkinson’s Disease market report include:
  • Abbott Laboratories
  • Aleva Neurotherapeutics SA
  • Beijing PINS Medical Co., Ltd.
  • Bioinduction Ltd.
  • Boston Scientific Corporation
  • Deep Brain Innovations LLC
  • FHC, Inc.
  • Functional Neuromodulation Ltd.
  • Inomed Medizintechnik GmbH
  • Integer Holdings Corporation
  • LivaNova, plc
  • Magstim Company Ltd.
  • Medtronic plc
  • Neurology Solutions
  • NeuroMetrix, Inc.
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • Newronika S.r.l.
  • Nuvectra Corporation
  • Renishaw plc
  • SceneRay Corporation Ltd.
  • Soterix Medical Inc.
  • Suzhou PINS Medical Co., Ltd.
  • Synapse Biomedical, Inc.
  • Zynex, Inc.

Table Information

Report AttributeDetails
No. of Pages198
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.61 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.02 Billion
Compound Annual Growth Rate16.1%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Deep Brain Stimulation Devices Market - Global Forecast 2026-2032 - Product Image

Deep Brain Stimulation Devices Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Deep Brain Stimulation in Parkinson's Disease - Global Strategic Business Report - Product Image

Deep Brain Stimulation in Parkinson's Disease - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
Closed Loop Neurostimulator Market - Global Forecast 2025-2030 - Product Image

Closed Loop Neurostimulator Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Implantable Neurostimulation Device Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Implantable Neurostimulation Device Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Deep Brain Stimulation In Parkinson Disease Market

Deep brain stimulation (DBS) for Parkinson's disease is a therapeutic procedure aimed at managing the symptoms of this neurodegenerative disorder when medication is insufficient or leads to undesirable side effects. This method involves the surgical implantation of electrodes within certain areas of the brain, generating electrical impulses that regulate abnormal impulses. The DBS devices are an integral part of the Central Nervous System (CNS) drugs and devices domain, which encompasses a broad range of therapies for various neurological conditions, including medication, neuromodulation devices, and support services. Within this context, DBS acts as an adjunct to pharmacological treatments, offering an alternative for patients with advanced Parkinson's disease. While CNS drugs typically address the dopaminergic deficits inherent to Parkinson's disease pathophysiology through oral or injectable medications, DBS provides a unique mechanistic approach by directly modulating brain activity and circuits involved in motor control. The procedure is generally reserved for patients exhibiting motor fluctuations and tremors that are not adequately controlled by medication. Several industry players are active in the DBS market for Parkinson's disease. Key companies engaged in the development and provision of DBS systems include Medtronic, Boston Scientific, and Abbott Laboratories. These entities continuously engage in research and development to advance the technology, increase its efficacy, and reduce any associated risks, thereby improving the lives of patients with Parkinson's disease. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.